Status:
TERMINATED
DELFT (Dynepo Evaluation of Long-Term Follow-Up Treatment)
Lead Sponsor:
Shire
Conditions:
Anemia
Kidney Diseases
Eligibility:
All Genders
Brief Summary
This is a post-authorisation safety study to assess the incidence and severity of all pre-defined cardiovascular events in patients treated with DYNEPO, as well as to detect \& describe less common ad...
Eligibility Criteria
Inclusion
- Adult patients must have established Chronic Kidney Disease (CKD) and be willing and able to provide written informed consent.
- Patients must already be receiving DYNEPO treatment at time of study entry.
- Patients who are likely to receive DYNEPO for at least 1 year.
Exclusion
- Known intolerance to EPO of any of its excipients
- Known of suspected Pure Red Cell Aplasia (PRCA)
Key Trial Info
Start Date :
April 25 2008
Trial Type :
OBSERVATIONAL
Allocation :
ACTUAL
End Date :
July 30 2008
Estimated Enrollment :
3 Patients enrolled
Trial Details
Trial ID
NCT00664066
Start Date
April 25 2008
End Date
July 30 2008
Last Update
June 25 2021
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Nephrologische Zentrum Villingen-Schwenningen
Villingen-Schwenningen, Baden-Wurttemberg, Germany, 78054
2
Hanse-Klinikum Stralsund
Stralsund, Germany